オプションチェーンは、Intelligent Bio Solutionsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Intelligent Bio Solutionsの市場センチメントを評価します。.

Intelligent Bio Solutions (NASDAQ:INBS) 株価情報, オプションチェーン

Intelligent Bio Solutions

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions Inc

PMV Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMVP#NASDAQ">PMVP</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

Earnings

Earnings Beats

News

PMVP

PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate

Needham analyst Bernie McTernan reiterates Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) from Hold to Hold.

Reiteration

Analyst Ratings

PTON

Needham Reiterates Hold on Peloton Interactiveto Hold

WIIM

PAR stock has given up its prior gain. PAR Technology shares were trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Overweight and lowers the price target from $45 to $38.

Price Target

FDMT

Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $38

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.5% on Friday.
Shares of Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) fell sharply in today's pre-market trading after the company reported <a href="https://in.benzinga.com/general/travel/25/05/45303916/expedia-stock-trades-down-on-q1-revenue-miss-weaker-than-expected-demand-in-the-us">worse-than-expected Q1 sales results.</a>
Expedia reported first-quarter revenue of $2.99 billion, up 3% year-over-year. The revenue total missed a Street consensus estimate of $3.01 billion according to data from Benzinga Pro.
Expedia Group shares dipped 9.8% to $152.40 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Jade Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares tumbled 44.4% to $5.00 in pre-market trading.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) shares dipped 35.6% to $2.04 in pre-market trading after the company reported worse-than-expected first-quarter financial results.</li>
<li>Profound Medical Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) fell 34.7% to $3.25 in pre-market trading after posting downbeat quarterly earnings.</li>
<li>Globus Medical, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) tumbled 17.2% to $60.00 in pre-market trading after the company reported worse-than-expected first-quarter financial results and cut its FY25 adjusted EPS guidance below estimates.</li>
<li>FIGS, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) fell 16.2% to $4.22 in pre-market trading after reporting first-quarter results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 13.2% to $3.84 in pre-market trading after reporting mixed quarterly results.</li>
<li>Onto Innovation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) dipped 11.6% to $112.00 in pre-market trading after the company issued weak forecast for the second quarter.</li>
<li>OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>) declined 7% to $14.31 in pre-market trading following downbeat quarterly results.</li>
<li>Grindr Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRND#NYSE">GRND</a>) dipped 6.7% to $22.80 in pre-market trading after the company reported worse-than-expected quarterly sales results.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) dipped 6.3% to $50.82 in pre-market trading following third-quarter results.</li>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) fell 4.7% to $629.00 in pre-market trading after the company reported first0quarter financial results. The company issued second-quarter adjusted EPS guidance below estimates.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Movers

Trading Ideas

AFRM

EXPE

FIGS

GMED

GRND

HUBS

IOVA

JBIO

ONTO

PROF

WOLF

Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session

TELUS (TSX:<a class="ticker" href="https://www.benzinga.com/stock/T#TSX">T</a>) reported quarterly earnings of $0.26 per share which beat the analyst consensus estimate of $0.22 by 18.18 percent. This is unchanged from the same period last year. The company reported quarterly sales of $5.06 billion which beat the analyst consensus estimate of $5.02 billion by 0.74 percent. This is a 2.53 percent increase over sales of $4.93 billion the same period last year.

TSX:T

TELUS Q1 Adj. EPS $0.26 Beats $0.22 Estimate, Sales $5.06B Beat $5.02B Estimate

Domain Board unanimously recommended that Domain shareholders vote in favor of the proposed Scheme
CoStar Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), a leading provider of online real estate marketplaces, information, analytics and 3D digital twin technology in the property markets, announced today that it has entered a binding Scheme Implementation Deed (SID) to acquire 100% of the issued capital of Domain Holdings Australia Limited, a leading Australian property marketplace.
In February 2025, CoStar Group acquired approximately 17% of the ordinary shares of Domain at A$4.20 per share for a total purchase price of approximately A$452 million ($285 million). Under the terms of SID, which followed a period of exclusive due diligence, CoStar Group has agreed to pay Domain shareholders a cash consideration of A$4.43 per share, less any special dividend declared or paid by Domain from May 9, 2025, for the balance of the shares by way of a Scheme of Arrangement (Scheme). The consideration to be offered to Domain shareholders values Domain at an implied enterprise value of A$3.0 billion. Accordingly, CoStar Group expects to spend approximately A$2.3 billion ($1.5 billion) to acquire the remaining approximately 83% of the ordinary shares of Domain that it doesn't otherwise own upon consummation of the Scheme.

CSGP

CoStar Group Enters Binding SID To Acquire 100% Of Issued Capital Of Domain Holdings Australia In A$3 Bln Deal

AVGO climbs up over 7 points
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/08201258/Screenshot-2025-05-08-at-4.12.31%E2%80%AFPM-1024x1006.png" alt="" class="wp-image-12660" /></figure>
Broadcom, Inc. (AVGO) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 11:00 AM on May 8th, a significant trading signal occurred for Broadcom, Inc. (AVGO) as it demonstrated a Power Inflow at a price of $204.41. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Broadcom&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Broadcom&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for AVGO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $204.41. The returns on the High price ($211.16) and Close price ($207.77) after the Power Inflow are respectively 3.3% and 1.6%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

Technicals

Opinion

Signals

AVGO

Broadcom Stock Rises Over 3% After Key Signal

Needham analyst Bernie McTernan reiterates Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) from Hold to Hold.

LYFT

Needham Reiterates Hold on Lyftto Hold

<h3>Gainers</h3>
<ul>
<li>Zapp Electric Vehicles Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) shares moved upwards by 67.8% to $0.52 during Friday's pre-market session. The market value of their outstanding shares is at $4.0 million. </li>
<li>Fox Factory Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXF#NASDAQ">FOXF</a>) stock rose 8.92% to $23.26. The market value of their outstanding shares is at $970.0 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock rose 8.28% to $0.43. The market value of their outstanding shares is at $15.0 million. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares moved upwards by 7.95% to $6.65. The company's market cap stands at $1.2 billion. </li>
<li>TCTM Kids IT Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSA#NASDAQ">VSA</a>) stock increased by 6.78% to $0.75. The market value of their outstanding shares is at $7.4 million. </li>
<li>Tile Shop Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTSH#NASDAQ">TTSH</a>) shares rose 6.58% to $6.47. The market value of their outstanding shares is at $289.4 million. As per the news, the Q1 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) stock decreased by 41.1% to $4.39 during Friday's pre-market session. The market value of their outstanding shares is at $6.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>1-800-Flowers.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLWS#NASDAQ">FLWS</a>) shares decreased by 16.24% to $4.85. The company's market cap stands at $309.6 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Universal Electronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UEIC#NASDAQ">UEIC</a>) stock declined by 15.18% to $5.2. The company's market cap stands at $68.3 million. The company's, Q1 earnings came out yesterday. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares decreased by 14.29% to $0.9. </li>
<li>FIGS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIGS#NYSE">FIGS</a>) shares declined by 13.07% to $4.39. The market value of their outstanding shares is at $713.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) stock decreased by 11.95% to $1.18. The market value of their outstanding shares is at $41.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ECDA

FLWS

FOXF

HOUR

SHCO

TTSH

UEIC

VEEE

ZAPP

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock increased by 79.5% to $0.48 during Friday's pre-market session. The company's market cap stands at $3.0 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 51.0% to $0.83. The market value of their outstanding shares is at $1.9 million. </li>
<li>Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) stock increased by 29.85% to $4.35. The company's market cap stands at $296.5 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares increased by 24.77% to $1.36. The company's market cap stands at $108.9 million. </li>
<li>Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>) shares increased by 18.62% to $0.43. The company's market cap stands at $28.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li>Adicet Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACET#NASDAQ">ACET</a>) stock rose 16.82% to $0.56. The company's market cap stands at $46.2 million. The company's, Q1 earnings came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Jade Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) shares decreased by 44.5% to $5.0 during Friday's pre-market session. The market value of their outstanding shares is at $263.0 million. </li>
<li>Varex Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares declined by 42.2% to $5.0. The company's market cap stands at $206.1 million. As per the press release, Q2 earnings came out yesterday. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 41.5% to $0.06. </li>
<li>Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) stock decreased by 35.02% to $2.06. The company's market cap stands at $687.9 million. The company's, Q1 earnings came out yesterday. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares declined by 30.93% to $0.41. The company's market cap stands at $2.7 million. </li>
<li>Protalix BioTherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PLX#AMEX">PLX</a>) stock fell 26.65% to $2.12. The market value of their outstanding shares is at $168.5 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACET

CRVS

CTMX

GBIO

NCNA

PLRZ

SHPH

VREX

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock rose 15.7% to $1.4 during Friday's pre-market session. The market value of their outstanding shares is at $22.7 million. </li>
<li>FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) stock rose 14.34% to $0.63. The market value of their outstanding shares is at $6.0 million. </li>
<li>Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) shares rose 11.76% to $14.53. The market value of their outstanding shares is at $6.1 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Power Solutions Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIX#NASDAQ">PSIX</a>) stock moved upwards by 10.63% to $30.7. The market value of their outstanding shares is at $706.3 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Nuvve Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVVE#NASDAQ">NVVE</a>) shares rose 9.64% to $1.25. The market value of their outstanding shares is at $3.8 million. </li>
<li>IBEX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBEX#NASDAQ">IBEX</a>) shares increased by 9.08% to $27.99. The company's market cap stands at $369.2 million. As per the news, the Q3 earnings report came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Solidion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STI#NASDAQ">STI</a>) stock declined by 27.0% to $0.12 during Friday's pre-market session. The company's market cap stands at $15.6 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares fell 16.54% to $0.47. The company's market cap stands at $3.3 million. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares declined by 9.8% to $4.41. The market value of their outstanding shares is at $220.7 million. </li>
<li>Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) stock fell 9.2% to $7.01. The company's market cap stands at $189.7 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li>Gencor Industries (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GENC#AMEX">GENC</a>) stock declined by 8.54% to $12.0. The market value of their outstanding shares is at $175.8 million. </li>
<li>Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) shares decreased by 6.35% to $38.5. The market value of their outstanding shares is at $1.2 billion. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DXST

ELPW

GENC

IBEX

INOD

NVVE

PSIX

SGBX

12 Industrials Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>nLight (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASR#NASDAQ">LASR</a>) stock increased by 29.8% to $11.18 during Friday's pre-market session. The market value of their outstanding shares is at $552.7 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares increased by 14.51% to $0.45. The company's market cap stands at $63.5 million. As per the press release, Q1 earnings came out today. </li>
<li>Mitek Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MITK#NASDAQ">MITK</a>) stock increased by 13.28% to $9.98. The market value of their outstanding shares is at $451.5 million. As per the news, the Q2 earnings report came out yesterday. </li>
<li>Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) shares increased by 11.53% to $138.65. The market value of their outstanding shares is at $48.0 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>JFrog (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>) stock rose 9.01% to $38.44. The market value of their outstanding shares is at $4.3 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) stock moved upwards by 8.87% to $53.5. The market value of their outstanding shares is at $28.7 billion. The company's, Q4 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) stock fell 19.9% to $3.55 during Friday's pre-market session. The company's market cap stands at $552.2 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Intellicheck (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDN#NASDAQ">IDN</a>) stock decreased by 19.0% to $2.26. The market value of their outstanding shares is at $44.7 million. </li>
<li>Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) stock declined by 12.07% to $1.75. The market value of their outstanding shares is at $78.4 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) stock fell 9.32% to $115.0. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>Eastman Kodak (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) stock fell 7.47% to $6.2. The company's market cap stands at $499.7 million. As per the press release, Q1 earnings came out yesterday. </li>
<li>AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) stock decreased by 6.62% to $0.53. The market value of their outstanding shares is at $9.8 million. As per the news, the Q1 earnings report came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FROG

INUV

KODK

LASR

LIDR

MCHP

MITK

VERI

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16
Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill
PN-881, a first-in-class oral peptide targeting the IL-17 pathway, potently and selectively binds IL-17A and -17F, blocking the three dimeric forms of the cytokine
&nbsp;Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced new clinical data from the Phase 3 ICONIC-TOTAL a study investigating icotrokinra, the first-in-class oral peptide antagonist targeting IL-23 receptor and preclinical characterization of PN-881, the first-in-class oral peptide antagonist blocking the three dimeric forms of IL-17 (AA, AF and FF), were presented separately today at the 2025 Society for Investigative Dermatology (SID) Annual Meeting in San Diego, CA.
The ICONIC-TOTAL study, conducted by Protagonist's collaboration partner, Johnson &amp; Johnson, evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.
Key findings from the high-impact skin sites cohort of the icotrokinra ICONIC-TOTAL study [1] :
At week 16, 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an Investigator's Global Assessment (IGA) b score of 0/1 (clear or almost clear skin) and a ≥2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo (P&lt;0.001).
66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P&lt;0.001) at 16 weeks.
77% of patients with genital psoriasis achieved a static Physician's Global Assessment of Genitalia (sPGA-G) d score of 0/1 compared to 21% receiving placebo (P&lt;0.001) at 16 weeks.
In the smaller subset of patients with hand/foot psoriasis, patients showed a numerically higher rate of skin clearance at Week 16 with 42% achieving a hand and/or foot Physician's Global Assessment (hf-PGA) e score of 0/1 compared to 26% receiving placebo.
Icotrokinra demonstrated a favorable safety profile. A similar proportion of patients experienced adverse events (50% and 42%) and serious adverse events (0.5% and 1.9%) in icotrokinra and placebo respectively through Week 16, with no new safety signals identified.
PN-881 represents Protagonist's next generation of oral peptides for psoriasis. Key takeaways from the pre-clinical characterization of the IL-17 oral peptide antagonist PN-881 [2] :
Exhibited nanomolar to picomolar in vitro potency comparable to bimekizumab and superior (70-fold) to secukinumab.
Showed metabolic stability in several matrices across several species, making it a suitable candidate for oral delivery.
Demonstrated PD-based target engagement in a mouse IL-17 challenge model after oral dosing
Demonstrated dose-dependent efficacy with significant reduction in skin thickness in a 5-day rat IL-23 induced skin inflammation model after oral dosing.
"High-impact skin sites affected by psoriasis can be very challenging to treat effectively and patients often experience unique challenges profoundly impacting their daily lives," said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. "The data presented by our partner today demonstrate that icotrokinra continues to have the potential to transform the current treatment paradigm based on the impressive results achieved with a convenient targeted therapy in the form of a once-daily pill. Additionally, we are thrilled to share the first detailed characterization of our next drug candidate in the I&amp;I space, PN-881, the first-in-class oral peptide antagonist targeting the three dimeric forms of IL-17, including AA, AF, and FF. We look forward to progressing our fully owned asset PN-881 in human clinical studies in Q4 2025."

Biotech

General

PTGX

Protagonist Announces Icotrokinra Phase 3 Data On PN-881 Presented At Society For Investigative Dermatology Annual Meeting

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Wells Fargo analyst Gabe Hajde downgraded Packaging Corp of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PKG#NYSE">PKG</a>) from Overweight to Equal-Weight and lowered the price target from $205 to $180. Packaging Corp of America shares closed at $183.42 on Thursday. <a href="https://www.benzinga.com/quote/PKG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Swayampakula Ramakanth downgraded the rating for Vor Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) from Buy to Neutral. Vor Biopharma shares closed at $0.16 on Thursday. <a href="https://www.benzinga.com/quote/VOR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Robbie Marcus downgraded CVRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVRX#NASDAQ">CVRX</a>) from Neutral to Underweight and slashed the price target from $15 to $7. CVRx shares closed at $7.78 on Thursday. <a href="https://www.benzinga.com/quote/CVRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gabe Hajde downgraded the rating for International Paper Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IP#NYSE">IP</a>) from Equal-Weight to Underweight and cut the price target from $45 to $40. International Paper shares closed at $44.92 on Thursday. <a href="https://www.benzinga.com/quote/IP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Samik Chatterjee downgraded Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) from Neutral to Underweight. Wolfspeed shares closed at $4.43 on Thursday. <a href="https://www.benzinga.com/quote/WOLF/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying IP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="566" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09080718/image-105-1024x566.png" alt="" class="wp-image-910030" style="width:599px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09080718/image-105-1024x566.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09080718/image-105-300x166.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09080718/image-105-768x425.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/09080718/image-105.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45285413/top-3-financial-stocks-which-could-rescue-your-portfolio-this-month">Top 3 Financial Stocks Which Could Rescue Your Portfolio This Month</a> </li>
</ul>
Photo via Shutterstock

Downgrades

CVRX

This International Paper Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday

Mediobanca (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDIBY#OTC">MDIBY</a>) reported quarterly earnings of $0.89 per share. This is a 28.23 percent decrease over earnings of $1.24 per share from the same period last year. The company reported $967.48 million in sales this quarter. This is a 0.76 percent decrease over sales of $974.84 million the same period last year.

MDIBY

Mediobanca Q3 Adj. EPS $0.89 Down From $1.24 YoY, Sales $967.48M Down From $974.84M YoY

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next eight years. This partnership, which has the potential to be the largest ever industry-academic agreement of its kind in the United States, will seek to accelerate innovation at every stage of the pharmaceutical pipeline.
The Lilly-Purdue 360 Initiative aims to achieve several key goals, including discovering and accelerating the delivery of medicines to patients; bridging the gap between laboratory discoveries and clinical applications; creating more resilient, efficient and sustainable supply chains; and deploying innovative, scalable approaches to workforce development. The expanded collaboration is also expected to generate significant economic benefits for Indiana by creating a highly skilled workforce and fostering local innovation.
The earlier agreement, which had been set to expire in 2027, will now extend with four new projects added through 2032. Additionally, it will engage existing joint programs, such as Lilly Scholars at Purdue and the Lilly and Purdue Research Alliance Center (LPRC). Purdue will make space available for Lilly researchers on-site in West Lafayette. Purdue researchers will collaborate in Lilly facilities in Indianapolis and in Indiana's LEAP Research and Innovation District.

Eli Lilly Plans To Expand Purdue University Collaboration With Up To $250M Investment To Accelerate Pharmaceutical Pipeline

Set to Debut in October 2025, the New Viking Thoth Will be Viking's Eighth River Vessel in Egypt
Viking&#xAE; (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.viking.com%2F&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=www.viking.com&amp;index=1&amp;md5=70f03769a3196b14bb80d0d625f6a3d8">www.viking.com</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) today announced its newest ship for the Nile River—the 82-guest <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-thoth.html%3Fmsockid%3D3e52097180f064fc0e5a1d4d81f06598&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Thoth&amp;index=2&amp;md5=bdd4a95e15a1116197908941b752dd2f">Viking Thoth</a>—was "floated out," marking a major construction milestone and the first time the ship has touched water. Set for delivery in October 2025, the Viking Thoth will join Viking's growing fleet of state-of-the-art ships for the Nile River and will sail Viking's popular 12-day <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fcruise-destinations%2Fegypt%2Fpharaohs-pyramids%2F2024-cairo-cairo%2Findex.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Pharaohs+%26amp%3B+Pyramids&amp;index=3&amp;md5=ddf91fe93272fc7c6dd432c0b7e44c20">Pharaohs &amp; Pyramids </a>itinerary.
"Egypt is a country of profound historical and cultural significance, which makes it a destination of great interest to our guests," said Torstein Hagen, Chairman and CEO of Viking. "With two new ships, the Viking Thoth and the Viking Amun, debuting in 2025, we are very proud to continue expanding our elegant fleet and introducing more curious travelers to this phenomenal region."
The traditional float out ceremony of the Viking Thoth was held at Massara shipyard in Cairo. It is significant because it marks the ship moving into its final stage of construction. The vessel will now be moved to a nearby outfitting dock for final construction and interior build-out.
The Viking Thoth &amp; Viking's Growing Egypt Fleet
Hosting 82 guests in 41 staterooms, the new, state-of-the-art <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-thoth.html%3Fmsockid%3D3e52097180f064fc0e5a1d4d81f06598&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Thoth&amp;index=4&amp;md5=162888de732c9535d0f30d506260480e">Viking Thoth</a>is inspired by Viking's award-winning river and ocean ships, with the signature Scandinavian design for which Viking is known. An identical sister ship to the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-osiris.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Osiris&amp;index=5&amp;md5=e5e20415bee7c9cf95574265650932a5">Viking Osiris</a>, the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-aton.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Aton&amp;index=6&amp;md5=82434d30b8792d5db387e453f5d5dbb8">Viking Aton</a>, the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-sobek.html%3Fadobe_mc%3DTS%253D1744398522%257CMCMID%253D77965057648886607002101786359557183283%257CMCORGID%253D8FC267C25245B36B0A490D4C%252540AdobeOrg%26_gl%3D1&#x2A;129wkfs&#x2A;_ga&#x2A;MTgxMTc3NzgzLjE3NDQzOTY3OTA.&#x2A;_ga_24KNYDH1S6&#x2A;MTc0NDM5Njc4OS4xLjEuMTc0NDM5ODIxOC41Ni4wLjA.&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Sobek&amp;index=7&amp;md5=58c4b5817b7098f10f9ba0151924d259">Viking Sobek</a>, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-hathor.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Hathor&amp;index=8&amp;md5=a510b11311cd5a58f3bcab0983c771f8">Viking Hathor</a> and the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-amun.html%3Fmsockid%3D3e52097180f064fc0e5a1d4d81f06598&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Amun&amp;index=9&amp;md5=2e8c4aa5d5ed28bf257df3be0689d561">Viking Amun</a>, the Viking Thoth features several aspects familiar to Viking guests, such as a distinctive square bow and an indoor/outdoor Aquavit Terrace. Other ships in Viking's Egypt fleet include the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fviking-ra.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=Viking+Ra&amp;index=10&amp;md5=1ccac7ea61927bb43b3fe14f7a72a6ee">Viking Ra</a> and the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.vikingrivercruises.com%2Fships%2Fegypt%2Fms-antares.html&amp;esheet=54251958&amp;newsitemid=20250509650666&amp;lan=en-US&amp;anchor=MS+Antares&amp;index=11&amp;md5=8ade9423e5af868a6d6db91aa22dabc8">MS Antares</a>. In addition to the Viking Thoth,Viking plans to welcome four new ships in Egypt in the next two years, which will bring Viking's fleet to 12 vessels on the Nile River by 2027.

Viking Announces Its Newest Ship For The Nile River, The 82-Guest Viking Thoth, Was "Floated Out," Marking Major Construction Milestone And Is Set For Delivery In October 2025

Johnson & Johnson Announced New Data From Phase 3 ICONIC-TOTAL Study Investigating Icotrokinra

Enbridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>) reported quarterly earnings of $0.72 per share which missed the analyst consensus estimate of $0.96 by 25 percent. This is a 5.88 percent increase over earnings of $0.68 per share from the same period last year. The company reported quarterly sales of $12.89 billion which missed the analyst consensus estimate of $14.23 billion by 9.40 percent. This is a 57.38 percent increase over sales of $8.19 billion the same period last year.

Earnings Misses

Enbridge Q1 Adj. EPS $0.72 Misses $0.96 Estimate, Sales $12.89B Miss $14.23B Estimate

Financing

Press Releases

Intelligent Bio Solutions Inc. Announces Closing of $3.0 Million Public Offering of Common Stock and Full Exercise of the Underwriter's Option to Purchase Additional Shares of Common Stock

Intelligent Bio Solutions to Participate in the iAccess Virtual Best Ideas Spring Conference on March 25th and 26th

Legal

Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

Intelligent Bio Solutions' FDA Clearance Process Remains on Track for 2025 U.S. Launch

Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry

Intelligent Bio Solutions Highlights Continued Expansion with Strategic Partnership in Spain and Andorra

Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

Intelligent Bio Solutions Expands Global Reach with Latin American Spanish Language Integration into Drug Screening System

Intelligent Bio Solutions Drives Global Growth Through Multilingual Digital Expansion

Comments

Intelligent Bio Solutions

Intelligent Bio Solutions (INBS) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル